Zobrazeno 1 - 5
of 5
pro vyhledávání: '"D. S. Romaniuk"'
Autor:
D. S. Romaniuk, A. A. Khmelevskaya, A. M. Postovskaya, D. B. Malko, E. P. Kuzminova, E. G. Khamaganova, G. A. Efimov
Publikováno v:
Медицинская иммунология, Vol 21, Iss 5, Pp 847-860 (2019)
Hematopoietic stem cell transplantation (HSCT) from healthy donors is used for blood cancer treatment. Alloreactive graft-versus-host disease (GvHD) is one of the post-transplant detrimental side effects, and the main reason for GVHD after HSCT fully
Externí odkaz:
https://doaj.org/article/acb19400962042fc9d8c8f2a9f51bf90
Autor:
D. S. Romaniuk, A. A. Khmelevskaya, M. Yu. Drokov, N. N. Popova, V. A. Vasilieva, L. A. Kuzmina, G. A. Efimov, E. N. Parovichnikova, V. G. Savchenko
Publikováno v:
Онкогематология, Vol 14, Iss 1, Pp 76-82 (2019)
Background. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is being widely applied as a therapy for hematological malignancies. The long-term outcome of allo-HSCT depends directly on the ability of cytotoxic T-lymphocytes to recognize
Externí odkaz:
https://doaj.org/article/1c51bc7aaee94e558d4ac9e6c9b7ebdb
Autor:
A. S. Vdovin, A. M. Postovskaya, N. A. Bykova, D. S. Romaniuk, A. K. Alieva, P. R. Yefimova, S. A. Sheetikov, H. L. Julhakyan, G. A. Efimov
Publikováno v:
Онкогематология, Vol 11, Iss 2, Pp 40-50 (2016)
The wide range of techniques could be employed to find mismatches in minor histocompatibility antigens between transplant recipients and their donors. In the current study we compared three genotyping methods based on polymerase chain reaction (PCR)
Externí odkaz:
https://doaj.org/article/56ac3bcec2c14acaa13bf175b25be732
Autor:
A. M. Pilunov, A. A. Kuchmiy, S. A. Sheetikov, S. Y. Filkin, D. S. Romaniuk, F. N. Rosov, G. A. Efimov
Publikováno v:
Molecular Biology. 53:402-410
Autor:
A M, Pilunov, A A, Kuchmiy, S A, Sheetikov, S Y, Filkin, D S, Romaniuk, F N, Rosov, G A, Efimov
Publikováno v:
Molekuliarnaia biologiia. 53(3)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy for hematopoietic malignancies. The graft-derived donor lymphocytes are capable of eliminating the residual recipient malignant cells in the course of allogen